导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.55% | 4028/4773 |
| 近一周 | -1.55% | 510/5462 |
| 近一月 | -0.02% | 700/5421 |
| 近一季 | -8.07% | 2668/5209 |
| 近半年 | -17.65% | 4200/4920 |
| 近一年 | -1.60% | 2900/4366 |
| 近两年 | 38.70% | 1948/2954 |
| 近三年 | 0.39% | 1919/2253 |
| 成立以来 | 13.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.97% 2590/4961 |
-2.31% 3396/5312 |
- - |
- - |
| 2025 | 28.11% 1506/4813 |
0.46% 1843/3635 |
12.89% 78/4076 |
5.64% 3573/4524 |
6.94% 326/4813 |
| 2024 | -0.84% 2134/3463 |
-13.26% 2478/2808 |
0.17% 644/3014 |
12.39% 2362/3129 |
1.55% 1053/3463 |
| 2023 | -21.37% 1900/2656 |
-7.30% 2174/2280 |
-0.28% 371/2385 |
-9.68% 1875/2515 |
-5.83% 1517/2655 |
| 2022 | -26.59% 1417/2207 |
-25.32% 1784/1919 |
7.69% 440/2016 |
-5.39% 76/2113 |
-3.52% 1854/2208 |
| 2021 | 13.29% 358/1822 |
-19.58% 1209/1255 |
10.96% 414/1330 |
6.64% 214/1466 |
19.06% 30/1822 |
| 2020 | 86.54% 28/1250 |
-0.26% 182/1028 |
14.99% 524/1067 |
29.53% 14/1164 |
25.58% 25/1184 |
| 2019 | 23.38% 628/1092 |
27.06% 364/754 |
-8.84% 613/804 |
4.37% 204/850 |
2.06% 871/918 |
| 2018 | -26.81% 401/834 |
- - |
- - |
- - |
-16.07% 623/691 |
| 2017 | -19.59% 577/714 |
- - |
- - |
- - |
- - |
| 2016 | -21.18% 453/605 |
- - |
- - |
- - |
- - |
| 2015 | 23.19% 100/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华国防A VS. 长安沪深300非周期A(740101) |